Nishi Kumari Selected Research

Neoplasms (Cancer)

1/2023	Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes.
10/2022	Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses.
1/2018	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.
12/2017	The roles of ubiquitin modifying enzymes in neoplastic disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nishi Kumari Research Topics

Disease

4	Neoplasms (Cancer) 01/2023 - 12/2017
2	Leukemia 10/2022 - 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022
1	Melanoma (Melanoma, Malignant) 01/2018
1	Carcinogenesis 12/2017

Drug/Important Bio-Agent (IBA)

1	histone H3 trimethyl Lys4IBA 01/2023
1	AntigensIBA 10/2022
1	Deubiquitinating EnzymesIBA 01/2020
1	ON 01910IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	raf KinasesIBA 01/2018
1	EnzymesIBA 12/2017
1	UbiquitinIBA 12/2017

Therapy/Procedure

1	Immunotherapy 10/2022
1	Stem Cell Transplantation 10/2022
1	Therapeutics 01/2018